Show simple item record

dc.contributor.authorPérez Arana, Gonzalo Martín 
dc.contributor.authorRibelles García, Antonio 
dc.contributor.authorPrada Oliveira, José Arturo 
dc.contributor.otherAnatomía y Embriología Humanaes_ES
dc.date.accessioned2022-07-08T09:59:51Z
dc.date.available2022-07-08T09:59:51Z
dc.date.issued2022-07-05
dc.identifier.urihttp://hdl.handle.net/10498/27147
dc.descriptionReview enviado a prensa especializada que requiere que el documento esté depositado en un repositorio institucional.es_ES
dc.description.abstractBackground: It has recently been proposed that biological activity of glucagon has a dual function beyond stimulating hepatic glucose production, but also showing a paradoxical insulinotropic effect, which could suppose a new role of glucagon in the pathophysiological mechanisms of type 2 diabetes mellitus (T2DM). On the other hand, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have also been developed, with surprising effects against T2DM. The aim of this review is to collect the information about the role of glucagon in pathophysiologic events involved in T2DM improvement after these surgeries. Results: After reviewing the 160 articles included in this study, an insulinotropic role for glucagon after B/M surgery through GLP1r in the beta-cell population arises. This effect seems to be modulated by another proglucagon family members such as GLP-1, GIP or Oxintomodulin, playing a key function on the B/M surgery beneficial effects and complications. Conclusions: Glucagon has a dual role after RYGB or SG. In addition to maintain blood glucose level it shows an insulinotropic effect which leads to be more than an “anti-insulin hormone”.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGlucagones_ES
dc.subjectdiabeteses_ES
dc.subjectsleeve gastrectomyes_ES
dc.subjectRoux-en-Y gastric bypasses_ES
dc.subjectincretines_ES
dc.subjectglucosees_ES
dc.subjectalpha celles_ES
dc.titleThe role of glucagon after bariatric/metabolic surgery: much more than an “anti-insulin” hormone.es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.description.physDescReview en inglés. 36 páginas.es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional